SAB4200322

Anti-OSTF1 (N-terminal) antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody

• Synonym(s): Anti-OSF1, Anti-Osteoclast-stimulating factor 1
• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: rabbit
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• form: buffered aqueous solution
• mol wt: antigen ~26 kDa
• species reactivity: human
• concentration: ~1.0 mg/mL
• technique(s): immunoprecipitation (IP): 2.5-5.0 μg using lysates of HEK-293T cells over expressing human OSTF1; western blot: 2-4 μg/mL using using HEK-293 cells overexpressing human OSTF1
• UniProt accession no.: Q92882
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... OSTF1(26578) ; mouse ... Ostf1(20409) ; rat ... Ostf1(259275)

Description

General description

Osteoclast-stimulating factor (OSF or OSTF1) is a small intracellular protein with a N-terminal proline-rich region, SRC Homology 3 (SH3) domain, three ankyrin repeats and a C-terminal aspartate-rich region. The OSF gene is mapped to human chromosome 9q21.13. OSF is expressed in osteoclast (OCL) as well as motor neurons. Structurally, OCF protein takes up a β-barrel fold.

Specificity

Anti-OSTF1 (N-terminal) recognizes human OSTF1.

Immunogen

synthetic peptide corresponding to the N-terminal region of human OSTF1, conjugated to KLH. The corresponding sequence is identical in rat and mouse.

Application

Anti-OSTF1 (N-terminal) antibody produced in rabbit may be used in immunoblotting and immunoprecipitation.

Biochem/physiol Actions

Osteoclast-stimulating factor (OSF or OSTF1) SRC Homology 3 (SH3) domain undergoes conformational changes to bind to proline-rich ligand. The C-terminal ankyrin repeats preferably binds to negative-charged binding partners. OSF plays an indirect role in osteoclast (OCL) formation as well as bone resorption. It favors OCL formation by interacting with sarcoma proto oncogene (c-Src) and its associated protein-based signaling pathway. OSF is implicated in the pathophysiology of spinal muscular atrophy by its possible interaction with survival motor neuron (SMN) proteins through the SH3 domain. OSF-SH3 domain interaction stimulates OCL formation and its inhibition may reduce bone resorption by OCL. A compromised bone resorption functionality in OCL further triggers bone loss and may lead to various bone disorders, including hyperparathyroidism, Paget′s disease, osteoporosis, estrogen deficiency, periodontal disease as well as inflammatory bone loss and bone malignancy.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers,is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Disclaimer

Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class: 10 - Combustible liquids
• flash_point_f: Not applicable
• flash_point_c: Not applicable